Survivin expression in “low-risk” and “high-risk” myelodysplastic syndromesUmberto Gianelli, Silvano Bòsari, Federica Savi et al.|Annals of Hematology|2006Cited by 19
Bone marrow glycophorin‐positive erythroid cells of myelodysplastic patients responding to high‐dose rHuEPO therapy have a different gene expression pattern from those of nonrespondersAgostino Cortelezzi, Nicola Stefano Fracchiolla, Gualtiero I. Colombo et al.|American Journal of Hematology|2008Cited by 10